[
  {
    "role": "user",
    "id": "c5c4fec3-128c-4300-8fd4-2bc85b148965",
    "content": "By what mechanism does Palovarotene treat Fibrodysplasia Ossificans Progressiva (FOP)?"
  },
  {
    "role": "assistant",
    "tool_calls": [
      {
        "type": "function",
        "id": "call_ot0ROfrH1YnV1QDnUEqGawja",
        "function": {
          "name": "task",
          "arguments": "{\"description\": \"Identify key entities related to the question about the mechanism by which Palovarotene treats Fibrodysplasia Ossificans Progressiva (FOP).\", \"subagent_type\": \"anchor_specialist\"}"
        }
      }
    ],
    "id": "lc_run--019c3c9a-55bd-72c1-8cc7-f4338e697624",
    "content": ""
  },
  {
    "role": "tool",
    "name": "task",
    "tool_call_id": "call_ot0ROfrH1YnV1QDnUEqGawja",
    "id": "78d577bc-b24c-4125-8771-7c95336de767",
    "content": "Here's a summary of the resolved entities related to the question about the mechanism by which Palovarotene treats Fibrodysplasia Ossificans Progressiva (FOP):\n\n```json\n{\n  \"entities\": [\n    {\"mention\": \"Palovarotene\", \"type\": \"Drug\", \"curie\": \"CHEMBL:2105648\", \"status\": \"resolved\", \"name\": \"Palovarotene\"},\n    {\"mention\": \"Fibrodysplasia Ossificans Progressiva\", \"type\": \"Disease\", \"curie\": \"MONDO:0018875\", \"status\": \"resolved\", \"name\": \"Fibrodysplasia Ossificans Progressiva\"}\n  ],\n  \"unresolved\": []\n}\n```\n\n- **Palovarotene (CHEMBL:2105648)** is a compound confirmed for the treatment of FOP.\n- **Fibrodysplasia Ossificans Progressiva (FOP)** has several associated clinical trials, specifically mentioning Palovarotene as an intervention.\n\nIf more in-depth genetic information, such as the involvement of the ACVR1 gene often associated with FOP, is needed, further search could be undertaken to establish connections at a genetic level."
  },
  {
    "role": "assistant",
    "tool_calls": [
      {
        "type": "function",
        "id": "call_8XzGop3kvmURauC4bKK4BWu1",
        "function": {
          "name": "task",
          "arguments": "{\"description\": \"Enrich the following entities to gather more data including UniProt IDs, Ensembl IDs, and functional descriptions: CHEMBL:2105648 (Palovarotene), MONDO:0018875 (Fibrodysplasia Ossificans Progressiva). We aim to understand the mechanism by which Palovarotene treats FOP.\", \"subagent_type\": \"enrichment_specialist\"}"
        }
      }
    ],
    "id": "lc_run--019c3c9a-8fa3-7b70-ba46-9259e1afb0f7",
    "content": ""
  },
  {
    "role": "tool",
    "name": "task",
    "tool_call_id": "call_8XzGop3kvmURauC4bKK4BWu1",
    "id": "7dd1fad2-5ef0-4e72-bbae-70f7fa65ee30",
    "content": "Here are the enriched details for Palovarotene (CHEMBL:2105648) and the related disease Fibrodysplasia Ossificans Progressiva (FOP):\n\n### Palovarotene (CHEMBL:2105648)\n- **Max Phase**: 4\n- **Indications**: Dry Eye Syndromes, Myositis Ossificans, Ossification, Heterotopic\n- **Mechanism of Action**: Palovarotene is an orally bioavailable selective retinoic acid receptor (RAR) \u03b3 agonist. It inhibits bone morphogenetic protein and SMAD 1/5/8 signaling, preventing chondrogenesis and allowing normal muscle tissue repair or regeneration. It is specifically used to reduce heterotopic ossification (HO) formation in patients with fibrodysplasia ossificans progressiva (FOP). \n\n### Insights from Literature on FOP and Palovarotene:\n1. **Palovarotene's Mechanism**:\n   - It works by binding to the retinoic acid receptor \u03b3, thereby inhibiting pathways that promote excessive bone formation outside the skeleton.\n   - Blocks the bone morphogenetic protein and SMAD 1/5/8 signaling pathway involved in undesired bone growth. \n\n2. **Overview from Articles**:\n   - *Palovarotene: First Approval*: Established as a treatment to reduce HO in adults and children with FOP.\n   - *Therapeutic Advances*: FOP results in heterotopic bone formation due to mutations in the ACVR1 gene, leading to abnormal signaling that palovarotene helps modulate.\n   - *Current and Emerging Treatment Modalities*: Approval of Palovarotene marks significant progress, though long-term safety and efficacy are still under evaluation.\n\n3. **Expert Opinions**:\n   - Although Palovarotene provides therapeutic benefits in reducing new HO formation, concerns about its generalized use and long-term implications exist.\n\nBased on the above, Palovarotene is seen as a pioneering therapy in managing FOP by targeting specific signaling pathways that contribute to the disease's pathology.\n\nIf you need further exploration or details concerning other entities, feel free to ask!"
  },
  {
    "role": "assistant",
    "tool_calls": [
      {
        "type": "function",
        "id": "call_PAU2pN2XFiGS2bDM9FPPEaxz",
        "function": {
          "name": "task",
          "arguments": "{\"description\": \"Investigate the biological interactions and pathways involving Palovarotene (CHEMBL:2105648) in the context of treating Fibrodysplasia Ossificans Progressiva (MONDO:0018875). This includes examining STRING interactions and WikiPathways for relevant signaling mechanisms.\", \"subagent_type\": \"expansion_specialist\"}"
        }
      }
    ],
    "id": "lc_run--019c3c9a-dd2e-7513-9cec-79f5d6ea4323",
    "content": ""
  },
  {
    "role": "tool",
    "name": "task",
    "tool_call_id": "call_PAU2pN2XFiGS2bDM9FPPEaxz",
    "id": "fb98e362-ca0a-42f2-9644-17385eabcbcd",
    "content": "Here's a summary of the relevant interactions and pathways involving Palovarotene, particularly through its known target, RARA, in the context of treating Fibrodysplasia Ossificans Progressiva (FOP):\n\n### Interactions\n- **RARA (Retinoic Acid Receptor Alpha)**: This is the primary target for Palovarotene.\n- **STRING Interactions**: High-confidence interactions (scores close to or exceeding 0.99) with:\n  - **RXRG**, **RARB**, **RXRB**: Other retinoic acid receptor forms.\n  - **NCOA1**, **NCOA2**: Nuclear receptor coactivators.\n  - **NCOR1**, **NCOR2**: Nuclear receptor corepressors.\n  - **ZBTB16**, **PML**: Other interactions related to transcription regulation and cellular differentiation.\n\n### Pathways\n- **Signaling by Retinoic Acid**: Directly involved in modulating gene expression by binding to RARA.\n- **Vitamins A and D - Action Mechanisms**: Linked to RARA\u2019s activity, highlighting the broader context of retinoic acid in signaling processes.\n\n### Strategic Insights\nThese interactions and pathways show the critical role of RARA in gene expression modulation affecting cellular differentiation, an essential process potentially contributing to the pathological bone formation seen in FOP. Palovarotene's action on RARA could prove beneficial in modulating these processes, providing a therapeutic angle for addressing FOP.\n\nFor a deeper understanding of how these mechanisms impact FOP specifically, further detailed studies focusing on cellular and molecular changes in FOP contexts would be valuable."
  },
  {
    "role": "assistant",
    "tool_calls": [
      {
        "type": "function",
        "id": "call_lYkDQGRLSKvEAFyOKOG99FfO",
        "function": {
          "name": "task",
          "arguments": "{\"description\": \"Find drugs targeting ACVR1 (implicated gene in Fibrodysplasia Ossificans Progressiva). Try ChEMBL first, fall back to Open Targets if needed.\", \"subagent_type\": \"traversal_drugs_specialist\"}"
        }
      },
      {
        "type": "function",
        "id": "call_XQHRhdvKDqUVaKhgCupKv2ye",
        "function": {
          "name": "task",
          "arguments": "{\"description\": \"Identify clinical trials associated with Palovarotene (CHEMBL:2105648) in the context of Fibrodysplasia Ossificans Progressiva (FOP). Use the ClinicalTrials.gov API to find relevant trials with NCT IDs.\", \"subagent_type\": \"traversal_trials_specialist\"}"
        }
      }
    ],
    "id": "lc_run--019c3c9b-45e6-7680-984e-cd2d4fc337d9",
    "content": ""
  },
  {
    "role": "tool",
    "name": "task",
    "tool_call_id": "call_lYkDQGRLSKvEAFyOKOG99FfO",
    "id": "6df987fe-baa6-428d-ae43-c7f5ba9b15dc",
    "content": "Here are the drugs targeting ACVR1, identified as activin receptor type-1 agonists:\n\n```json\n{\n  \"drugs\": [\n    {\n      \"name\": \"Eptotermin alfa\",\n      \"chembl_id\": null,\n      \"phase\": 4,\n      \"mechanism\": \"Activin receptor type-1 agonist\",\n      \"source\": \"Open Targets\"\n    },\n    {\n      \"name\": \"Dibotermin alfa\",\n      \"chembl_id\": null,\n      \"phase\": 4,\n      \"mechanism\": \"Activin receptor type-1 agonist\",\n      \"source\": \"Open Targets\"\n    }\n  ],\n  \"target_ensembl_id\": \"ENSG00000115170\"\n}\n```\n\nThese drugs are in advanced phases, indicating some level of clinical validation. Both are recognized for their action on activin receptor pathways."
  },
  {
    "role": "tool",
    "name": "task",
    "tool_call_id": "call_XQHRhdvKDqUVaKhgCupKv2ye",
    "id": "5b041af3-ee05-4588-aa34-57b15078319f",
    "content": "Here are the clinical trials associated with Palovarotene in the context of Fibrodysplasia Ossificans Progressiva (FOP):\n\n```json\n{\n  \"trials\": [\n    {\"nct_id\": \"NCT04829773\", \"title\": \"An Open-Label Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects\", \"phase\": null, \"status\": \"COMPLETED\", \"drug\": \"Palovarotene\"},\n    {\"nct_id\": \"NCT02279095\", \"title\": \"A Phase 2, Open-Label Extension, Efficacy and Safety Study of a Retinoic Acid Receptor Gamma (RAR\u03b3) Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)\", \"phase\": null, \"status\": \"COMPLETED\", \"drug\": \"Palovarotene\"},\n    {\"nct_id\": \"NCT05027802\", \"title\": \"Rollover Study; Multicentre, Phase III, Open-label Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged \u226514 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed Study PVO-1A-301 or PVO-1A-202/PVO-1A-204 and May Benefit From Palovarotene Therapy.\", \"phase\": null, \"status\": \"COMPLETED\", \"drug\": \"Palovarotene\"},\n    {\"nct_id\": \"NCT02322255\", \"title\": \"A Natural History, Non-Interventional, Two-Part Study in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)\", \"phase\": null, \"status\": \"COMPLETED\", \"drug\": \"Palovarotene\"},\n    {\"nct_id\": \"NCT06089616\", \"title\": \"An International Observational Registry Study to Further Describe Long-term Safety and Effectiveness of Palovarotene in Patients With Fibrodysplasia Ossificans Progressiva (FOP)\", \"phase\": null, \"status\": \"RECRUITING\", \"drug\": \"Palovarotene\"},\n    {\"nct_id\": \"NCT02521792\", \"title\": \"A Phase 2, In-Home, Safety and Efficacy Evaluation of Episodic Administration of Open-Label Palovarotene in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)\", \"phase\": null, \"status\": \"TERMINATED\", \"drug\": \"Palovarotene\"},\n    {\"nct_id\": \"NCT03312634\", \"title\": \"A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)\", \"phase\": null, \"status\": \"COMPLETED\", \"drug\": \"Palovarotene\"},\n    {\"nct_id\": \"NCT02190747\", \"title\": \"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of a RAR\u03b3-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)\", \"phase\": null, \"status\": \"COMPLETED\", \"drug\": \"Palovarotene\"}\n  ]\n}\n```\n\nThese trials provide a comprehensive view of Palovarotene's evaluation in treating FOP, addressing various aspects of its safety, efficacy, and pharmacokinetics."
  },
  {
    "role": "assistant",
    "tool_calls": [
      {
        "type": "function",
        "id": "call_3iEVoJXmqvIsOOvZy8jWbh8d",
        "function": {
          "name": "task",
          "arguments": "{\"description\": \"Validate all gathered information including identifiers like NCT IDs for trials, phases for drugs, mechanisms of action, and any claims about Palovarotene and ACVR1's involvement in FOP treatment using PubMed literature and other reliable sources.\", \"subagent_type\": \"validation_specialist\"}"
        }
      }
    ],
    "id": "lc_run--019c3c9b-e302-7d53-86e3-53276b2967f2",
    "content": ""
  },
  {
    "role": "tool",
    "name": "task",
    "tool_call_id": "call_3iEVoJXmqvIsOOvZy8jWbh8d",
    "id": "e29c5806-843a-4741-8a81-5cc5f483c4e7",
    "content": "Based on the validation checks, here's the status of claims related to Palovarotene and its use in treating Fibrodysplasia Ossificans Progressiva (FOP):\n\n1. **Claim**: \"NCT03312634 is a Phase 3 trial for Palovarotene in FOP\"\n   - **Verdict**: VALIDATED\n   - **Evidence**: Direct lookup on ClinicalTrials.gov confirmed the trial as a Phase 3 study of Palovarotene for FOP.\n\n2. **Claim**: \"Palovarotene targets ACVR1 pathway\"\n   - **Verdict**: PARTIALLY VALIDATED\n   - **Evidence**: The search results from ChEMBL indicate Palovarotene as a compound but do not directly confirm the mechanism targeting ACVR1. However, literature from PubMed (PMID: 39451784) discusses Palovarotene's role in reducing heterotopic ossification, which is related to ACVR1 mutations in FOP, indirectly supporting the claim.\n\nThe findings uphold the existing claims regarding the trial and suggest a mechanistic connection between Palovarotene and the ACVR1 pathway based on literature, though specific mechanistic details of ACVR1 targeting were only indirectly verified through literature context."
  },
  {
    "role": "assistant",
    "tool_calls": [
      {
        "type": "function",
        "id": "call_xIbZsyvMbUQ7Z698OplmJl2q",
        "function": {
          "name": "task",
          "arguments": "{\"description\": \"Summarize and finalize the collected and verified information about the mechanism by which Palovarotene treats Fibrodysplasia Ossificans Progressiva (FOP), including drug targets, mechanism of action, relevant clinical trials, and validation outcomes.\", \"subagent_type\": \"persistence_specialist\"}"
        }
      }
    ],
    "id": "lc_run--019c3c9c-2a0a-7aa3-818f-962ef5b484d0",
    "content": ""
  },
  {
    "role": "tool",
    "name": "task",
    "tool_call_id": "call_xIbZsyvMbUQ7Z698OplmJl2q",
    "id": "11363520-72db-49c1-81d2-536e48f7b563",
    "content": "Given the current environment, I am unable to persist data to Graphiti. However, I will provide a structured summary of the validated information regarding Palovarotene's mechanism in treating Fibrodysplasia Ossificans Progressiva (FOP).\n\n## Summary\nPalovarotene is investigated as a treatment for Fibrodysplasia Ossificans Progressiva (FOP) due to its mechanism of action related to inhibiting bone growth processes. It functions by targeting the ACVR1 gene, which is implicated in the inappropriate bone growth seen in FOP. This inhibitory action helps manage and potentially reduce the occurrence of heterotopic ossification characteristic of FOP.\n\n## Resolved Entities\n| Entity | CURIE | Type |\n|--------|-------|------|\n| ACVR1 | HGNC:171 | Gene |\n\n## Key Findings\n- **Palovarotene** targets the ACVR1 gene, which plays a key role in the abnormal bone growth process seen in FOP patients. [Source: Clinical Trial documentation]\n- The drug is currently in Phase 3 clinical trials specifically for treating FOP. [Source: Clinical Trial database]\n\n## Drug Candidates\n| Drug | Phase | Mechanism | Source |\n|------|-------|-----------|--------|\n| Palovarotene | 3 | Targets ACVR1 to inhibit bone growth | Clinical Trial documentation |\n\n## Clinical Trials\nThe information indicates active Phase 3 clinical trials aiming to establish the efficacy and safety of Palovarotene for FOP treatment. Specific trial identifiers (e.g., NCT ID) were not provided, and further detailed research would be necessary to list these identifiers.\n\n## Confidence\nThe confidence in Palovarotene's potential as a treatment for FOP is high, given its progression to Phase 3 trials, indicating significant prior success in earlier phases. Continued close observation of ongoing trial results will be crucial for full validation.\n\nIf more detailed data from verified sources regarding clinical trials or additional mechanisms are available, they should be reviewed and integrated here."
  },
  {
    "role": "assistant",
    "id": "lc_run--019c3c9c-4d47-7193-aa1a-4e91cf477906",
    "content": "Palovarotene treats Fibrodysplasia Ossificans Progressiva (FOP) by inhibiting key pathways associated with abnormal bone growth. It primarily acts on the retinoic acid receptor gamma to block bone morphogenetic protein (BMP) signaling, which is crucial in reducing heterotopic ossification\u2014a hallmark of FOP. Trials have verified Palovarotene's safety and efficacy up to Phase 3, emphasizing its role in managing FOP by targeting abnormal bone formation processes linked to the ACVR1 gene mutation."
  }
]